Iron Chelation Therapy in Myelodysplastic Syndromes by Messa, Emanuela et al.
Hindawi Publishing Corporation
Advances in Hematology
Volume 2010, Article ID 756289, 8 pages
doi:10.1155/2010/756289
Review Article
Iron Chelation Therapy in Myelodysplastic Syndromes
EmanuelaMessa,DanielaCilloni,andGiuseppeSaglio
Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin,
Regione Gonzole 10, 10043 Orbassano (To), Italy
Correspondence should be addressed to Giuseppe Saglio, giuseppe.saglio@unito.it
Received 1 October 2009; Revised 18 January 2010; Accepted 20 April 2010
Academic Editor: Jeﬀery Lynn Miller
Copyright © 2010 Emanuela Messa et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by
anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload.
Iron chelation therapy may be a therapeutic option for these patients, especially since the approval of oral iron chelators, which
are easier to use and better accepted by the patients. The usefulness of iron chelation in MDS patients is still under debate, mainly
because of the lack of solid prospective clinical trials that should take place in the future. This review aims to summarize what is
currently known about the incidence and clinical consequences of iron overload in MDS patients and the state-of the-art of iron
chelation therapy in this setting. We also give an overview of clinical guidelines for chelation in MDS published to date and some
perspectives for the future.
1.Introduction
Myelodysplastic syndromes (MDS) are clonal disorders of
the hematopoietic stem cell and are mainly characterized
by bone marrow blasts up to 20%, one or more peripheral
cytopenias and bone marrow dysplasia [1]. The prognosis
can be variable, with survival ranging from a few months
to many years, and depends on the three features evaluated
by the International Prognostic Scoring System (IPSS) [2]:
cytogenetic abnormalities, percentage of blasts in the bone
marrow, and number of peripheral cytopenias. Among so
wide a spectrum of clinical features, clinicians must choose
from diﬀerent therapeutic options (reviewed in [3]), that
vary from supportive care or growth factoradministration to
chemotherapy or bone marrow transplantation in younger
and higher risk cases. New therapeutic options are now
available; some of them, addressed to patients with speciﬁc
cytogenetic features, such as lenalidomide for patients with
5q-. Other promising medications are the hypomethylating
agents, which may improve survival in higher risk subjects
[3].
Lower-risk MDS patients often become transfusion-
dependent during the course of the disease, which can be
quite long, and this could contribute to increased cardiac
morbidity and mortality. It is well known that transfusion
dependency is an important prognostic factor in MDS and
portends worse prognosis [4]. Similarly, high ferritin level in
refractory anemia, but not in refractory cytopenia without
anemia, is a negative prognostic factor for survival [5].
However, it should be kept in mind that more aggressive
disease is frequently associated with a high transfusion
rate, so signiﬁcant transfusion dependency often becomes a
surrogate marker of aggressive disease.
Blood transfusion therapy may lead to organ toxicity
due to the formation of nontransferrin bound iron (NTBI)
and resulting oxidative stress, as is well documented in
transfusion-dependent congenital anemias [6]. In low-risk
MDSpatientswithlongerlifeexpectancy,preventingdamage
due to iron overload is an important concern. In fact,
several authors underline the importance of iron chelation
as a prognostic variable for improving survival [7, 8]. The
data, however, are mainly derived from retrospective studies
and need to be conﬁrmed in prospective trials. Recently,
Sanz et al. reported that iron overload (serum ferritin over
1000ng/mL) has a negative prognostic impact on leukemia-
free survival [9], suggesting that reactive oxygen species
(ROS), increased in iron overload, may be responsible for2 Advances in Hematology
DNA damage and disease progression in multiply transfused
patients. Furthermore, other therapeutic indications have
to be considered for iron chelation in MDS patients:
pretransplant high ferritin level has a negative prognostic
signiﬁcance for survival in acute myeloid leukemia (AML)
and MDS patients undergoing bone marrow transplantation
[10, 11]; so many reports underline the usefulness of
iron chelation for higher risk candidates for allografting.
Moreover, Pullarkat et al. [12] recently have proposed that
iron chelation may lower infection risk, delay leukemic
transformation, and improve hematologic parameters in
patients with higher IPSS scores who are not at this
point generally considered to be candidates for chelation
according to multiple guidelines [13–21]. This paper brieﬂy
summarizes what it is currently known about iron overload
and iron chelation in MDS.
2. Iron Overload in MDS
Chronic transfusion therapy is the main cause of iron
overload in MDS patients. It is well known from patients
aﬀected by congenital anemias that multiple transfusion
leadstotheformationofNTBI,whichincludesthelabileiron
pool (LIP) [6, 22]. This is deﬁned as the chelatable iron, able
to reach tissues and cells, and is thought to be responsible
for tissue damage, ﬁbrosis and organ failure, mainly aﬀecting
the liver, heart and pancreas [6]. Several reports describe
organ damage possibly due to multiple transfusions in MDS
patients[23,24].However,comorbiditiesoftenexist,making
it diﬃcult to discern how much organ damage is due to
transfusion therapy as opposed to age-related comorbidities.
Iron overload may have many clinical consequences in MDS
patients, which are brieﬂy summarized below.
3. IronOverloadandImpact on Survivaland
Leukemic Evolution
Several retrospective studies suggest an important contri-
bution of transfusion dependency in shortening survival in
MDS patients [25]. Malcovati et al. [26]r e p o r t e di nas e r i e s
of 467 MDS patients a high incidence of cardiac failure
(accounting for 51% of non leukemic deaths) in transfusion-
dependent MDS patients. It is not yet clear how signiﬁcant
is the contribution of iron overload from transfusions, and
how much is due to a higher disease severity in transfusion-
dependent patients. However, a reduced survival rate has
been observed in refractory anemia (RA) and refractory
anemia with ringed sideroblasts (RARS) patients but not
in refractory cytopenia with multilineage dysplasia (RCMD)
patients [5]. More recently, the same group highlighted
the importance of transfusion dependency for prognosis
whether we consider leukemia-free or overall survival [27,
28]. Similarly, Cermak et al. [29] reported a statistically
signiﬁcant negative impact on survival of transfusi on
dependency in MDS with erythroid dysplasia without excess
blasts. The importance of iron overload on morbidity and
mortality has been also shown by Takatoku et al. [30]. In this
retrospective study which included 292 patients aﬀected by
MDS,myeloﬁbrosisandaplasticanemia,97%ofdeathsfrom
cardiac and hepatic failure were observed in patients with a
serum ferritin level over 1000g/L. More recently, Sanz et al.
analyzedtheimpactofironoverloadinamulticenterstudyof
theSpanishgroupincluding2994patients[9].Amultivariate
analysis performed on 902 cases with complete data available
demonstrated a strong association between not only high
serum ferritin level and reduced survival (P<. 0001), but
also leukemia-free survival (P<. 0001) [7]. This is the
ﬁrst study evaluating the correlation between iron overload
and progression to leukemia, possibly suggesting a negative
inﬂuence of reactive oxygen species in inducing increased
genomicinstabilityinhematopoieticprogenitors,ashasbeen
demonstrated by in vitro and in vivo studies [31–33].
However, a strong and well-documented relation
between shorter survival and iron overload is still lacking
[34]. We need prospective studies able to correlate
more precisely iron overload parameters such as NTBI
measurement and appropriate magnetic imaging of the liver
and heart to survival and leukemic progression.
4.CardiacIronand TransfusionRate
Iron deposition in myocardial tissue is one of the most
concerning potential complications in MDS patients receiv-
ing chronic transfusion therapy. It is well known that
secondary hemocromatosis in thalassemia patients and in
othercongenitalanemiasleadstocardiacirondepositionand
heart failure [35]. Many studies in recent years addressing
this point in transfused MDS patients have been published.
In this clinical setting we must consider that there is
a shorter transfusional history compared with congenital
anemias, and that other factors besides iron deposition
could be involved in increased cardiac failure in transfused
patients, such as anemia and MDS severity. Cardiac iron
accumulation in MDS can be variable and there are many
studies reporting conﬂicting results in this regard. In an
autopsy series of transfusion-dependent patients, Buja and
Roberts [36] found a direct correlation between the number
of red cell transfusions and the amount of iron deposition.
More recently, studies based on MRI T2∗ imaging suggest
that cardiac iron accumulation is not a frequent feature of
MDSpatients [37]and does not correlate withserumferritin
levels or hepatic iron overload [38, 39] but only with the size
of the chelatable iron pool [40].
5. Iron Overload and Riskof Infection
There are numerous observations suggesting an increased
risk of infection in iron loaded patients, particularly those
aﬀected by acute leukemia or allogenic stem cell trans-
plantation (SCT) recipients [41–43]. In these conditions,
there is a coexistence of many factors able to enhance
infectious susceptibility, such as neutrophil dysfunction,
severe cytopenias and an increase in labile plasma iron (LPI)
due either to a high transfusion rate or to myelosuppressive
therapies. However, even if iron chelation can be useful in
this setting in preventing bacterial and fungal infections,Advances in Hematology 3
it is important to correctly choose the appropriate chela-
tion agent: it has been suggested that deferoxamine can
worsen fungal infections by acting as a siderophore [44]. In
contrast, it has been demonstrated that deferasirox can be
eﬀective against mucormicosis infection in vivo [45]. So, as
suggested recently by Pullarkat, iron chelators could have
a possible new role in the future, lowering infection risks
in MDS, expecially in high risk patients with more severe
neutropenia [12].
6. Iron Overloadin Transplantation
In recent years, diﬀerent studies highlighted iron overload
as a negative prognostic indicator in patients undergoing
stem cell transplantation (SCT). In a cohort of 590 patients
who underwent myeloablative SCT, Armand et al. [10]
found a strong negative association between high serum
ferritin level and overall and disease-free survival. This
association was seen in patients aﬀected by acute myeloid
leukemia or myelodysplastic syndrome. The ﬁve-year overall
survival decreased from 54% for patients with serum ferritin
under 231ng/mL to 27% for those with serum ferritin
higher than 2034ng/mL. Additionally, in MDS patients a
serum ferritin higher than 2034ng/mL was associated with
a signiﬁcantly increased transplant-related mortality (hazard
ratio = 3,2), no correlation was found between serum
ferritin level and relapse rate, however. Similar results have
also been published by Pullarkat et al., who analyzed 190
patients undergoing SCT: in a multivariate analysis high
pretransplant serum ferritin (above 1000ng/ml) strongly
correlated with an increased risk of death (hazard ratio 2,28,
P = .004), day 100 mortality (odds ratio in generalized
linear models of 3,82, P = .013), bloodstream infection
(odds ratio = 3,11) and acute graft versus host disease
(odds ratio = 1,99) [11]. The 190 patients were followed
for a mean of 209 days: 27 died in the ﬁrst 100 days
and 29 after this cut oﬀ. The results of Cox proportional
hazards model showed a higher risk of death in high-ferritin
group (P = .004). More recently, Mahindra et al. studied
222 patients who underwent myeloablative allogeneic bone
marrow transplantation: pretransplantation serum ferritin
above 1910μg/l was strongly associated with lower overall
and relapse-free survival (P = .003 for both the variables)
and with lower incidence of chronic and acute graft versus
host disease (P = .019 and 0,10, resp.). No diﬀerences were
observed in relapse mortality and incidence of hepatic veno-
occlusive disease between patients stratiﬁed according the
serum ferritin value of 1910μg/l [46]. A higher morbidity
rate in iron loaded transplant recipients has been shown by
Au et al. [47]: high iron levels measured by T2∗ MRI mostly
intheliver,pancreasandpituitaryglandwereassociatedwith
abnormal pancreas and pituitary function in 40%–70% of
patients studied.
During the SCT procedure and follow up, serum fer-
ritin and NTBI levels are markedly increased by several
mechanisms (reviewed in [48]), increasing the risk of infec-
tions, mucositis, chronic liver disease, sinusoidal obstruction
syndrome and idiopathic pneumonia. Therefore, reducing
iron burden after SCT may be helpful in lowering the risk
of infection [49] and organ toxicity, and can be achieved
by phlebotomy in patients with a normal hemoglobin.
Prospective clinical trials to evaluate the eﬀectiveness and
safety of iron chelators in this setting are ongoing [48].
7.I r o nCh elatio ninMDS
7.1. Iron Chelators Commercially Available. Currently, three
iron chelators are commercially available: deferoxamine
(DFO), deferasirox (DFR) and deferiprone (DFP). DFO was
introduced in the 1970s and had a profound impact on the
survival of thalassemia patients [50]. In such patients the
drug reduced organ dysfunctions and mortality, restoring a
life expectancy similar to normal individuals with a survival
rate strictly correlating to days of deferoxiamine infusions
[51]. Due to its short half life, DFO is administered by
subcutaneous infusion 5 to 7 nights/week, though it may be
diﬃcult to use in MDS patients due to thrombocytopenia.
More recently, two oral agents have been introduced: the
three-times daily agent deferiprone and the once-daily
deferasirox [52–54]. DFP is eﬀective in reducing hepatic
and cardiac iron content in thalassemia patients, but its
clinical use is partially limited by the risk of occurrence
of agranulocytosis. This concerning adverse eﬀect is rare,
but potentially harmful in thalassemia and also in MDS,
where pancytopenia is a common clinical feature. The
latter agent, deferasirox, is administered once daily due
to a long half life, and has been recently released on the
market for the treatment of secondary iron overload in
transfusion-dependent anemias. Several clinical studies
evaluating the eﬃcacy and safety of deferasirox in many
transfusion-dependent congenital anemias have been
published [55–58]. Moreover, its usefulness has also been
tested in a cohort of MDS patients, yielding good data on
eﬃcacy and safety in this older population [59, 60]. Its
side eﬀects are generally mild, consisting mainly of nausea,
diarrhea and a self-limiting serum creatinine increase, thus
making this agent possibly the most suitable for chelation
therapy in the MDS population [61]. We should also keep
in mind the recent guidance from FDA regarding the
use of deferasirox in MDS patients where a greater risk
for adverse events such as kidney failure, gastrointestinal
hemorrhage and deaths is reported for myelodysplastic
patients compared to others without this condition (http://
www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo-
rmationforPatientsandProviders/DrugSafety).
7.2. Impact of Iron Chelation on Survival in MDS. Two retro-
spective studies reported a positive impact of iron chelation
on the survival of MDS patients: Leitch et al. analyzed a
population of 178 MDS patients from the University of
British Columbia database, revealing a positive association
b e t w e e ni r o nc h e l a t i o na n ds u r v i v a li nas u b c o h o r to f
28 matched patients [7]. In a multivariate analysis iron
chelation therapy (based on deferoxamine administration by
subcutaneous infusion for at least 12 hours per day and 5
days per week) was a signiﬁcant factor for overall survival4 Advances in Hematology
(P = .01, hazard ratio 0,29). Similar results have been
obtained also in a partially prospective analysis performed
on a population of 170 MDS patients from 18 hematological
centers in France. Rose et al. analyzed survival data in
a cohort of MDS patients referred for transfusions in a
month period in all the French centers involved. Data on
survival were collected prospectively whereas transfusion
and previous clinical history retrospectively. Among the
cohort of iron chelated patients, 19 received deferoxamine
treatment by intermittent bolus, 57 DFO by infusion for
more than 3 days per week or, alternatively, DFP or DFR.
The authors observed an improvement in overall survival
in patients who underwent iron chelation therapy using a
multivariate analysis: overall survival was 115 months in
the chelated group versus 51 months in the nonchelated
patients with a statistically signiﬁcant diﬀerence (P = .0001)
[8]. Although these data are promising, ad hoc prospective,
controlled studies are needed in order to clarify the impact
of iron chelation on overall survival and leukemic evolution
in MDS.
7.3. Guidelines for Iron Chelation Therapy in MDS. Several
international guidelines, based mostly on the opinions of
expert panels, have been published in recent years, and their
main features are summarized in Table 1 a n dr e v i e w e db y
Gattermann[13].Concerningthethresholdofthenumberof
red blood cell (RBC) transfusion for starting iron chelation,
the Italian guidelines recommend chelation for patients
who reached an average of 50 RBC units, but only if they
have an expected lifespan of 6 months [14], while the UK
expert panel considers candidates for iron chelation MDS
patients who have received 25 units of blood and who
will receive ongoing transfusions [15]. A similar number of
previous transfusions is included in the NCCN (National
Comprehensive Cancer network) guidelines, where iron
chelation is suggested after the receipt of 20–30 units of RBC
[16]. The Japanese guidelines considered a higher threshold
of RBC units transfused; however, it should be noted that the
unit in this country is smaller [17].
Most guidelines suggest as an indicator of iron overload
a cut-oﬀ of serum ferritin level: even if ferritin is not
such a reliable indicator of iron overload, it is easily
obtained in clinical practice. The ferritin values indicated
vary slighty in the guidelines (see Table 1), but the majority
considered 1,000g/L as a reasonable threshold for starting
iron chelation. Serum ferritin evaluation is recommended
during iron chelation to establish eﬃcacy of the treatment at
least every three months in transfusion-dependent patients.
A useful and more reliable tool in monitoring iron overload
and iron chelation therapy is liver magnetic resonance but it
is not available in all centers. Monitoring of organ functions
(mainly cardiac, hepatic and endocrine) with appropriate
techniques is frequently indicated, other parameters such as
ROS, NTBI and LPI are under investigation [61]. Duration
of chelation has to be individually established and the
therapy has to be maintioned as long as transfusion therapy
continues or as long as iron overload remains clinically
relevant [18].
In summary, the majority of authors are in agreement
that iron chelation should be oﬀered to lower-risk MDS
patients with a life expectancy more than one year and
a serum ferritin above the mentioned threshold. Patients
who are candidates for allogenic transplantation or other
eﬀective therapies can also be considered candidates for
chelation.
7.4. Improvement in Hematopoiesis with Chelation. In some
patients with MDS receiving iron chelation, improved
hematopoiesishasbeennoted.Therearesomedataregarding
this eﬀect with deferoxamine and deferiprone. In 1996
Jensen et al. described a hemoglobin improvement in 11
MDS patients treated with deferoxamine for up to 60
months, but in some cases there was even a trilineage
response [62, 63]. It has also been reported that patients
with myeloﬁbrosis have a similar response to deferiprone
[64]. In all of these reports, the hematological response
was associated with a sharp decrease in iron burden and
the eﬀect was fairly long lasting, in the order of one year.
The eﬀect of deferasirox therapy seems to diﬀer: several
reports and our own experience have demonstrated an
unexpected improvement in hemoglobin level and reduction
in transfusion requirements even after only a few months
of chelation [65–67]. Three out of ﬁve patients described in
these reports became transfusion independent. A hemato-
logic improvement by World Health Organization (WHO)
criteria has also been recently described in clinical trials
with deferasirox in low and int-1 MDS patients [68]. The
hemopoiesis improvement has not yet been reported in any
patients aﬀected by thalassemia or other hereditary anemias,
but it seems not restricted to MDS patients, as several
cases of myeloﬁbrotic patients have been observed. It is not
yet clear which mechanism could lead to the hemoglobin
improvement and which patients could beneﬁt from this
eﬀect. Removing excess iron from erythroid precursors
could improve erythropoiesis, similar to what occurred in
a case of sideroblastic congenital anemia due to GLRX5
deﬁciency described recently by Camaschella et al. where
an eﬃcient iron chelation obtained by DFO subcutaneous
infusion led the patients to transfusion independence due to
a rebalancing in iron-responsive protein 1 and 2 functions
and intracellular iron distribution [69]. Also observed was a
reduced growth of erythroid colonies in vitro in iron-loaded
patients: the study performed by Hartmann et al. [70]o n4 2
peripheral blood samples of MDS patients demonstrated a
statistically signiﬁcant (P<. 004) reduced erythroid colony
formation in patients with high serum ferritin levels thus
supporting the hypothesis that iron chelation could induce
animprovementinhemopoiesis,perhapsbyreducingNTBI-
mediated toxicity or, alternatively, the phenomenon could be
explained by the more severity of bone marrow disease in
transfusion-dependent patients. It should be kept in mind,
however, that changes in hemopoiesis have been seen only
in a portion of patients, while NTBI detoxiﬁcation occurs
in all chelated subjects according to the drug used and its
type of administration. Our hypothesis to account for this
discrepancy is that deferasirox could interfere directly withAdvances in Hematology 5
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oncogenesintheMDSblastcell.Nuclearfactor-kappaB(NF-
κB) is a key regulator of many cellular processes and its
impaired activity has been described in diﬀerent myeloid
malignancies including MDS and could be a good potential
target of deferasirox activity. Preliminary in vitro analysis
demonstrated a deferasirox-dependent reduction in both
nuclear localization and activity of NF-κBi nM D Sc e l l sa n d
leukemia cell lines [71]. NF-κBe ﬀects were not detected in
cells incubated with DFO or DFP. The NF-κB inhibition
by deferasirox could prove to be an important therapeutic
option in higher risk MDS patients, targeting blast cells in
which increased NF-κB activity has been extensively demon-
strated,andactingasapossibleenhancerofchemosensitivity
of the neoplastic clone. Our promising hypothesis needs
obviously to be validated in vivo by prospective clinical
trials.
8. Conclusion
The usefulness and clinical indications of iron chelation
therapy in myelodysplastic syndrome patients are still under
debate within the scientiﬁc community [12, 72, 73]. Many
authors underline the deleterious eﬀect of iron deposition in
tissues due to secondary hemochromatosis, similar to what
occurs in the well-studied setting of congenital anemias.
These data are mainly derived from clinical studies showing
that transfusion dependence and high serum ferritin levels
are independent prognostic variables for reduced overall and
disease-free survival [4, 5]. High serum ferritin level was
also recently identiﬁed as a prognostic factor for shorter
time to progression to leukemia [9]. There are also data
showing an impact of iron chelation on survival, though
these data are from retrospective studies [7, 8]. The main
concern of experts not in favour of iron chelation is that
there is insuﬃcient evidence about the contribution of iron
overload to mortality rate and cardiac dysfunction in MDS
patients, and about a positive impact of iron chelation on
improving organ dysfunction, survival and quality of life.
Strongprospectivestudiesaddressingthesepointsareneeded
in the coming years, especially to address a putative survival
eﬀect. It is not yet clear which MDS patients could beneﬁt
most from iron chelation therapy: international guidelines
are not completely in agreement on serum ferritin threshold
level or number of RBC units transfused for starting iron
chelation [13]. Candidates for this therapy are mainly
lower-risk patients with a better prognosis and a longer
life expectancy, but patients who are candidates for SCT
or chemotherapy should also be included. More recently,
Pullarkat proposed to change our thinking about restricting
chelation to patients with lower risk MDS, considering
recent data about leukemic progression and incidence of
infection in iron loaded patients [12]. Finally, the data about
hemopoiesis improvement and NF-κB activity inhibition
have the potential to provide new insight into iron chelation
and its beneﬁcial eﬀects, all suggesting that higher risk MDS
patients may also be good candidates for this therapy [66–
68,71].Inouropinion,weshouldchangeourthinkingabout
iron chelation in MDS, expanding its indications from a
meresupportive therapyforpreventing organdamagedueto
RBC transfusions, to an active measure against progression
to leukemia.
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